Research Areas

Efficacy and Safety of an investigational medication Compared with Subcutaneous Human Insulin Therapy in Adult Subjects with Type 1 Diabetes Mellitus: A Two Year, Outpatient, Open-Label, Parallel-Group Comparative Trial.

A Randomized, Triple-Blind, Placebo-Controlled, Multicenter Study to Investigate the Safety of an investigational medication Treatment Employing investigational medication Dose-Titration Followed by Insulin Dose Optimization in Subjects with Type 1 Diabetes Mellitus Who Have Not Achieved Glycemic Targets With Intensive Insulin Therapy.

A Phase 2 Study of An Investigational Medication Compared with Insulin Glargine in the Treatment of Type 1 Diabetes Mellitus

Effects of A Marketed Glucose-Lowering Medication on Glucagon Suppression and GLP-1 Levels in Patients with Type 1 Diabetes

A Phase 2A Randomized Double-Blinded, Placebo and Active Controlled Two Cohort Two Doses Cross-Over Multi-Center Clinical Study to Assess Efficacy of a Once Daily Administration of an Investigational Medication for the Treatment of Vasospasm in Primary and Secondary Raynaud’s Phenomenon.

Collection of normal blood sample for use in a study of a new device to detect cancer cells in the blood

A Dose Range-finding, Double-blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety, Tolerability, and Efficacy of an Investigational Medication in Obese Subjects.

A Double Blind, Multi-Center, Randomized, Parallel-Group, Study to Assess the Efficacy and Safety 400 mg of An Investigational Medication and 120 mg of Orlistat Administered Individually or Combined Orally Three Times Per Day with a Reduced Calorie Diet (RCD) in Obese Subjects.

An Open Label Dose Escalation Study of an Investigational Medication in Patients With Painful Diabetic Neuropathy

A Phase IIb Repeat Dosing Clinical Trial of An Investigational Medication in Subjects with Moderately Severe Diabetic Neuropathy

A Multicenter, Randomized, Double-Blind, Parallel Group Study Comparing the Safety and Efficacy of Lotrel versus Amlodipine in the treatment of Moderate to Severe Hypertension.

Phase 2 multi-center, double-blind, placebo-controlled, randomized, parallel group, dose ranging study of the safety, efficacy and tolerability of an oral formulation of an investigational medication administered once a day for 8 weeks to subjects with moderate elevations in low-density lipoprotein cholesterol levels and without overt cardiovascular disease.

A multicenter, double-blind, randomized, placebo- and active-controlled, parallel study to evaluate the lipid altering efficacy and safety of an investigational medication in patients with metabolic syndrome and dyslipidemia

A comparison of treatment with an investigational medication and Simvastatin coadministration versus Simvastatin in attaining the National Cholesterol Educational Program (NCEP) Adult Treatment Panel (ATP) III coronary heart disease (CHD) or CHD risk equivalent strata low-density lipoprotein cholesterol (LDL-C) Target Level.

A randomized, double - blind, parallel, multicenter study to evaluate the efficacy and safety of Simvastatin monotherapy compared with simvastatin plus an investigational medication in Type 2 Diabetic patients treated with Thiazolidinediones.

A multicenter, randomized, double-blind, placebo-and-active-controlled parallel group dose-ranging study of an investigational medication in the treatment of hyperlipidemia

Phase 2 multi-center, double-blind investigational medication, placebo-controlled, randomized, parallel group, dose ranging study of the efficacy, safety, tolerability, and pharmacokinetics of an investigational medication and open-label atorvastatin when concurrently administered orally once daily (QD) for 12 weeks to subjects with elevated low-density lipoprotein cholesterol and without overt cardiovascular disease

Phase 2 multi-center, double-blind investigational medication, placebo-controlled, randomized, parallel group, dose ranging study of the efficacy, safety, tolerability, and pharmacokinetics of the investigational medication and open-label atorvastatin when concurrently administered orally twice daily (BID) for 12 weeks to subjects with elevated low-density lipoprotein cholesterol and without overt cardiovascular disease

An 8-Week, Double-Blind, Randomized, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of an investigational medication Administered in Combination With Atorvastatin or Alone to Hypercholesterolemic Patients

An Open Label Pilot Study To Assess the Safety of An Oral Investigational Medication as Adjunctive Therapy for Uncontrolled Primary Generalized Tonic-Clinic Seizures in Subjects with Idiopathic Generalized Epilepsy